Fundamentals Data provided by Morningstar.Data provided by Morningstar.
52 Week Range
Avg. Volume (1 month)
as at 24 Feb 3:44pm
Should you invest $1,000 in right now?
Before you consider , you’ll want to hear this.
Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and wasn’t one of them.
The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.
*Returns as of August 16th 2021
Why the MedAdvisor (ASX:MDR) share price jumped 12% today
Share Market News
The MedAdvisor (ASX:MDR) share price is lifting today. Here’s why
Why Brickworks, McPherson’s, MedAdvisor, & Premier Investments are storming higher
Share Market News
Why the Medadvisor (ASX:MDR) share price is up 11% this week
Why the MedAdvisor (ASX:MDR) share price is pushing higher today
2 ASX small cap healthcare shares growing quickly
Why Afterpay, Goodman, MedAdvisor, & PointsBet shares are dropping lower
Why the MedAdvisor (ASX:MDR) share price jumped 9% on Friday
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
|Date||Announcement||Price Sensitive?||Time||No. of Pages||File Size|
MedAdvisor Ltd is engaged in the development and deployment of the MedAdvisor medication and adherence platform. The MedAdvisor platform is focused on improving health outcomes by connecting health professionals with their patients using mobile and web technologies. It has five reporting segments: MedAdvisor; USA, UK, and Asia, and corporate. The company derives most of its revenues from MedAdvisor.
|16 May 2022||$0.20||$0.01||5.13%||46,364||$0.19||$0.20||$0.19|
|13 May 2022||$0.20||$0.01||5.26%||55,172||$0.20||$0.20||$0.20|
|12 May 2022||$0.19||$0.01||5.41%||253,366||$0.19||$0.20||$0.19|
|11 May 2022||$0.19||$0.00||0.00%||114,253||$0.19||$0.19||$0.18|
|10 May 2022||$0.19||$0.01||5.56%||32,992||$0.18||$0.19||$0.18|
|09 May 2022||$0.18||$-0.03||-14.29%||244,989||$0.22||$0.22||$0.18|
|06 May 2022||$0.21||$0.00||0.00%||131,857||$0.21||$0.21||$0.20|
|05 May 2022||$0.21||$-0.01||-4.65%||67,868||$0.22||$0.22||$0.21|
|04 May 2022||$0.22||$-0.01||-4.44%||93,215||$0.23||$0.24||$0.22|
|03 May 2022||$0.23||$0.01||4.65%||206,173||$0.22||$0.24||$0.22|
|02 May 2022||$0.22||$-0.04||-16.00%||251,455||$0.25||$0.25||$0.22|
|29 Apr 2022||$0.25||$-0.01||-3.92%||141,397||$0.26||$0.27||$0.25|
|28 Apr 2022||$0.26||$0.00||0.00%||21,936||$0.26||$0.27||$0.26|
|27 Apr 2022||$0.26||$-0.01||-3.85%||38,073||$0.27||$0.27||$0.26|
|26 Apr 2022||$0.26||$0.00||0.00%||18,288||$0.28||$0.28||$0.26|
|22 Apr 2022||$0.26||$-0.01||-3.77%||6,224||$0.26||$0.26||$0.26|
|21 Apr 2022||$0.27||$0.01||3.85%||48,969||$0.27||$0.27||$0.26|
|20 Apr 2022||$0.26||$0.00||0.00%||34,521||$0.26||$0.26||$0.26|
|09 May 2022||Robert Read||Exercise||2||$362,571|| |
Conversion of securities.
|09 May 2022||Robert Read||Exercise||535||$96,428|| |
Exercise of options.
|09 May 2022||Robert Read||Buy||535||$96,428|| |
Exercise of options.
|09 May 2022||Robert Read||Buy||2||$362,571|| |
Conversion of securities.
|26 Nov 2021||Robert Read||Issued||1||$577,500|| |
Issue of options.
|26 Nov 2021||Robert Read||Expiry||637||$245,437|| |
|26 Nov 2021||Lucas Merrow||Issued||750||$288,750|| |
Issue of options.
|17 Nov 2021||Jim Xenos||Sell||6||$2,464,903|| |
|Mr Robert Read||Chief Executive OfficerManaging Director||Nov 2015|| |
Mr Read has experience in a range of businesses, including Director of Strategy and Operations in one of the world's pharmaceutical companies, GSK and roles in venture capital and private equity. He has had roles in business consultancy and senior roles in private equity including Director at ANZ Private Equity and Managing Director at Harbert Private Equity, specialising in growth of small and medium sized businesses. He brings a range of skills to the position of CEO - including leadership, sales and marketing, financial performance improvement and a understanding of the requirements to grow businesses. He is a member of Risk and People Committee.
|Mr Jim Xenos||Non-Executive Director||Nov 2015|| |
Mr Xenos brings to the board pharmaceuticals industry experience and market insight and forge over 25 years and have lead teams to drive outcomes. He has a record of delivering market share across national and multinational corporations by creating brand and portfolio strategies, and by introducing new product offerings that leverage go-to market platforms in industry categories. He is a member of the Risk and People Committee.
|Mr Joshua Swinnerton||CTOExecutive Director||Nov 2015|| |
Mr Swinnerton has experience and manage sizeable IT ventures, as a consultant, and as the technical and Operation lead of start-up companies. He led a technology start-up which he also founded and sold into the US as well as raising funds in the US for the company's expansion and managed software development. During this time he gained experience in bridging the gap between technology and business objectives.
|Ms Linda Jenkinson||Non-Executive ChairmanNon-Executive Director||Feb 2022|| |
Ms Jenkinson is an experienced public and private company board director and a company CEO. Ms Jenkinson has worked as a CEO of high growth businesses for over 20 years and has built businesses spanning multiple countries and understands the US, Australian and New Zealand markets. Having co-founded five companies, including Dispatch Management Services (NASDAQ:DMSC), Ms Jenkinson was the third woman to list a company on NASDAQ. Prior to her time as CEO of DMSC and Les Concierges which she ran for 17 years, Ms Jenkinson spent 11 years as a strategy consultant and advisor to Fortune 500 CEOs and boards as a partner with A.T. Kearney and earlier in her career at Price Waterhouse. Ms Jenkinson currently serves as a non-executive director of the Eclipx Group Limited (ASX:ECX) and Harbour Asset Management Limited (NZ). She is Chair of Jaxsta Limited (ASX:JXT) and Guild Trustee Services Pty Limited.
|Ms Sandra Margaret Hook||Non-Executive Director||Jan 2016|| |
Ms Hook has over 25 years experience which include development and implementing business and brands to drive change. She has a record in delivering customer business transformation and transitioning organisations in evolving environments. She brings financial management experience of her career which includes CEO, COO, GM, Marketing Director and Snr Brand Manager with some of Australia's media companies including News Limited, Foxtel, Federal Publishing Company, Murdoch Magazines and Fairfax. She brings a focus on customer digital innovation at Board level. Since 2000 she has served as a non-executive director on listed, public and private companies, and government bodies. She is a trustee of the Sydney Harbour Federation Trust. She is Chair of Risk Committee and a member of People Committee.
|Mr Lucas Merrow||Non-Executive Director||Aug 2021|| |
Mr Merrow has experience in building Medtech enterprises, including Cotiviti/HMS-owned Eliza and the now MedAdvisor-owned Adheris. Having co-founded the MedAdvisor-owned Adheris in 1991, Merrow helped Adheris to grow a pharmacy network in the US with patient access, allowing Adheris to build a blue-chip customer base of many of the world's pharma companies. After Adheris, Mr Merrow cofounded Eliza Corporation which focusing on patient engagement and behaviour change on behalf of health insurers in the US.
|Ms RaeAnn Grossman||Non-Executive Director||Feb 2022|| |
Ms Grossman has experience in US healthcare having previously held senior roles at United Healthcare's Optum, Gorman Group and Censeo. She is currently the EVP of Population Health, Risk Adjustment and Quality at Cotiviti. Cotiviti is a healthcare technology business owned by Private Equity firm Veritas Capital.
|Ms Naomi Lawrie||General CounselCompany Secretary||Aug 2020|| |
|Naomi Lawrie||General CounselCompany Secretary|| |
|National Nominees Limited||58,898,879||15.61%|
|Cotiviti Services Llc||43,999,999||11.66%|
|Ebos Ph Pty Ltd||26,459,627||7.01%|
|J P Morgan Nominees Australia Pty Limited||23,252,284||6.16%|
|Kojent Pty Ltd (Kojent A/C)||20,540,866||5.44%|
|CS Third Nominees Pty Limited (HSBC Cust Nom Au Ltd 13 A/C)||15,671,261||4.15%|
|HSBC Custody Nominees (Australia) Limited||15,109,238||4.00%|
|Wavey Industries Pty Ltd (Josh Swinnerton Family A/C)||15,008,943||3.98%|
|Romida Enterprises Pty Ltd (Romida Family A/C)||13,173,035||3.49%|
|BNP Paribas Noms Pty Ltd (Drp)||9,834,268||2.61%|
|Provare Pty Ltd (Provare Investment A/C)||3,563,419||0.94%|
|Peloton Capital Pty Ltd||3,249,216||0.86%|
|Mishra Enterprises Pty Ltd (Mishra Family A/C)||2,894,737||0.77%|
|Gread Management Pty Limited (The A G & R R Family A/C)||2,864,285||0.76%|
|Dr Christopher Harold Benton||2,800,000||0.74%|
|Allen Group Holdings Pty Ltd||2,631,579||0.70%|
|Capital Concerns Pty Limited (Logue Family Super Fund A/C)||1,855,344||0.49%|
|Ethan Allen Investments Pty Ltd (Ethan Allen Invest Unit A/C)||1,773,794||0.47%|
|Dak Foundation Limited (Dak Foundation A/C)||1,700,000||0.45%|
|Canonbar Investments Pty Ltd||1,568,964||0.42%|